Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 13 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Closed				24 to 45				Pharmaceutical / Industry				2004_013 NCT00090220


2.		Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Completed				11 to 17				Pharmaceutical / Industry				2005_092 V501-025, NCT00325130


3.		Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Prevention				Completed				11 to 17				Pharmaceutical / Industry				2005_093 V501-024, NCT00337428


4.		Immunogenicity of GSK Bio's HPV Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Prevention				Completed				18 to 45				Pharmaceutical / Industry				108933 NCT00423046


5.		Safety, Tolerability and Immunogenicity of HPV Vaccine in Healthy Females 9 to 15 Years of Age in India.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Prevention				Completed				9 to 15				Pharmaceutical / Industry				2006_038 V501-029, NCT00380367


6.		An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Prevention				Closed				9 to 26				Pharmaceutical / Industry				2007_021 V501-030, NCT00496626


7.		A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Prevention				Completed				9 to 26				Other				H07-00928 BCGov-01, NCT00501137


8.		Broad Spectrum HPV Vaccine Dose Ranging Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Prevention				Completed				16 to 23				Pharmaceutical / Industry				2005_086 V502-001, NCT00260039


9.		V501 (Gardasil) Study in Preadolescent Females

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Prevention				Closed				9 to 17				Pharmaceutical / Industry				2006_052 V501-028, NCT00411749

Last Modified: 11/25/2008 First Published: 7/24/2007


10.		Phase II Pilot Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine in Male Patients With HIV-1 Infection

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				AMC-052 052, NCT00513526

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute